argenx

BenchSci announced a two-year enterprise agreement for argenx scientists to use EMET, its agentic research environment, in preclinical, computational and drug development workflows; argenx is quoted as testing whether it can accelerate preclinical development.

Partners: BenchSci

Chai Discovery announced a collaboration agreement giving argenx access to its AI platform to apply de novo antibody discovery across therapeutic targets.

Partners: Chai Discovery

Sequantrix announced an agreement with argenx for the use of its AI-driven DiseaseDecoder technology, a computational framework for identifying and evaluating targets.

Partners: Sequantrix

UC Santa Cruz reports that argenx and Unnatural Products entered a multi-target collaboration using UNP's platform, which combines AI-guided compound design, parallel synthesis and direct-to-biology screening, with up to about $1.5 billion in potential payments to UNP.

Partners: Unnatural Products